Replimune Group Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Replimune Group kazanç ve gelirinin sırasıyla yıllık 21% ve 57.4% oranında artması tahmin edilirken, EPS'nin yıllık 26.7% oranında büyümesi bekleniyor.

Anahtar bilgiler

21.0%

Kazanç büyüme oranı

26.7%

EPS büyüme oranı

Biotechs kazanç büyümesi	42.4%
Gelir büyüme oranı	57.4%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	22 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:7R8 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2027	101	-201	-235	N/A	3
3/31/2026	39	-227	-197	-147	5
3/31/2025	8	-221	-200	-156	7
9/30/2024	N/A	-213	-188	-181	N/A
6/30/2024	N/A	-220	-193	-186	N/A
3/31/2024	N/A	-216	-191	-185	N/A
12/31/2023	N/A	-210	-176	-172	N/A
9/30/2023	N/A	-199	-157	-154	N/A
6/30/2023	N/A	-182	-145	-143	N/A
3/31/2023	N/A	-174	-130	-128	N/A
12/31/2022	N/A	-157	-121	-118	N/A
9/30/2022	N/A	-147	-111	-108	N/A
6/30/2022	N/A	-133	-100	-97	N/A
3/31/2022	N/A	-118	-85	-82	N/A
12/31/2021	N/A	-108	-78	-76	N/A
9/30/2021	N/A	-100	-72	-70	N/A
6/30/2021	N/A	-91	-66	-65	N/A
3/31/2021	N/A	-81	-64	-61	N/A
12/31/2020	N/A	-75	-59	-57	N/A
9/30/2020	N/A	-70	-66	-59	N/A
6/30/2020	N/A	-61	-69	-62	N/A
3/31/2020	N/A	-53	-67	-61	N/A
12/31/2019	N/A	-43	-62	-55	N/A
9/30/2019	N/A	-35	-49	-46	N/A
6/30/2019	N/A	-30	-35	-32	N/A
3/31/2019	N/A	-31	-28	-25	N/A
12/31/2018	N/A	-31	-24	-24	N/A
9/30/2018	N/A	-28	-20	-20	N/A
6/30/2018	N/A	-26	N/A	-17	N/A
3/31/2018	N/A	-20	N/A	-16	N/A
12/31/2017	N/A	-17	N/A	-15	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 7R8 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: 7R8 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: 7R8 önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: 7R8 şirketinin gelirinin (yıllık 57.4% ) German pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 7R8 şirketinin gelirinin (yıllık 57.4% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 7R8 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Replimune Group Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2026

Recent updates

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Replimune Group, Inc. Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Presents Late-Breaking Abstract Featuring Data from Ignyte Clinical Trial of Rp1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc 2024)

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At European Society for Medical Oncology Congress 2024

Replimune Group, Inc. Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding

Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma

Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

Executive Chairman recently sold €226k worth of stock

Replimune Group, Inc. Announces Management Changes

Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $6.7 million.

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors

No longer forecast to breakeven

Replimune Group, Inc. Appoints Veleka R. Peeples-Dyer to Its Board of Directors

Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting

CEO & Director recently sold €298k worth of stock

No longer forecast to breakeven

Insufficient new directors

Replimune Group, Inc. Announces Executive Appointments

Now 23% undervalued

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

Replimune Group, Inc. announced that it has received $200 million in funding from Hercules Capital, Inc. and other investors

Replimune Group, Inc., Annual General Meeting, Sep 07, 2022

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 2000 Growth Index

Replimune Group, Inc. Announces the Resignation of Jason Rhodes from Its Board of Directors

Chief Commercial Officer recently sold €150k worth of stock

Replimune Group, Inc. Announces Updated Data from Completed Cohorts of the Phase 2 Part of the IGNYTE Clinical Trial in Non-Melanoma Skin Cancer (Nmsc) and Melanoma

Replimune Group, Inc. Announces Departure of Dr. Otello Stampacchia from its Board of Directors

Now 22% undervalued after recent price drop

Chief Medical Officer Andrea Pirzkall has left the company

Replimune Group, Inc.(NasdaqGS:REPL) dropped from Russell 3000E Index

Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1

Forecast to breakeven in 2026

Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma

New 90-day low: €30.40

Replimune Group, Inc. Announces First Patient Dosed with RP3 in a Phase 1 Clinical Trial in Patients with Advanced Solid Tumors

New 90-day high: €41.20

Replimune Group Inc. Announces Poster Presentations at the SITC 2020 Annual Meeting and a Presentation at the SITC 2020 Annual Meeting Virtual Press Conference

New 90-day high: €36.20

Replimune Group, Inc. Appoints Tanya Lewis to its Board of Directors, Effective November 2, 2020

Replimune Group, Inc. Announces Initial Clinical Data of Rp2 and Updated Clinical Data of RP1

New 90-day high - €21.40

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin